Literature DB >> 28698141

Epigenetic silencing of the Wnt antagonist APCDD1 by promoter DNA hyper-methylation contributes to osteosarcoma cell invasion and metastasis.

Weifeng Han1, Junpeng Liu2.   

Abstract

Osteosarcoma (OS) is the most common type of bone tumor in children and adults. However, the molecular mechanism underlying OS tumorigenesis remains unclear. Here, we report that the expression of APCDD1, a Wnt antagonist, was reduced in OS tissues and cells compared to adjacent normal tissue and osteoblast cells, respectively. Mechanistically, this was due to increased levels of methylation in the promoter region of the APCDD1 gene. Consistently, the DNA methyltransferase inhibitor 5-AZA-dC, reduced DNA methylation in the APCDD1 promoter, and restored APCDD1 expression in OS tissue and cells. Moreover, DNMT3a, but not DNMT1 or DNMT3b, was the major DNA methyltransferase that facilitated hyper-methylation of DNA in the APCDD1 promoter, thus reducing APCDD1 mRNA levels in OS tissues. Importantly, ectopic expression of APCDD1 suppressed activity of the Wnt/β-Catenin signaling pathway in OS cells and inhibited their invasion and reversed their EMT-like properties, while depletion of APCDD1 promoted invasion and metastasis of osteosarcoma cells in vitro and in vivo. Thus, we have provided the first evidence that APCDD1 expression is epigenetically silenced in OS, which may facilitate invasion and metastasis of OS cells.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  APCDD1; DNA methylation; Invasion and metastasis; Osteosarcoma; Wnt signaling

Mesh:

Substances:

Year:  2017        PMID: 28698141     DOI: 10.1016/j.bbrc.2017.07.049

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.

Authors:  Motonari Nomura; Nino Rainusso; Yi-Chien Lee; Brian Dawson; Cristian Coarfa; Ruolan Han; Jeffrey L Larson; Ryan Shuck; Lyazat Kurenbekova; Jason T Yustein
Journal:  J Natl Cancer Inst       Date:  2019-11-01       Impact factor: 13.506

2.  Methylation of secreted frizzled-related protein 1 (SFRP1) promoter downregulates Wnt/β-catenin activity in keloids.

Authors:  Jiaqi Liu; Huayu Zhu; Hongtao Wang; Jun Li; Fu Han; Yang Liu; Wanfu Zhang; Ting He; Na Li; Zhao Zheng; Dahai Hu
Journal:  J Mol Histol       Date:  2018-02-17       Impact factor: 2.611

3.  Knockdown of KCNQ1OT1 Suppresses Cell Invasion and Sensitizes Osteosarcoma Cells to CDDP by Upregulating DNMT1-Mediated Kcnq1 Expression.

Authors:  Xu Qi; Xiao-Jun Yu; Xu-Ming Wang; Tie-Nan Song; Jie Zhang; Xin-Zhen Guo; Guo-Jun Li; Ming Shao
Journal:  Mol Ther Nucleic Acids       Date:  2019-06-27       Impact factor: 8.886

4.  DNMT3A Regulates miR-149 DNA Methylation to Activate NOTCH1/Hedgehog Pathway to Promote the Development of Junctional Osteosarcoma.

Authors:  Shigao Cheng; Wanchun Wang
Journal:  Biomed Res Int       Date:  2022-07-21       Impact factor: 3.246

5.  Circ0038632 modulates MiR-186/DNMT3A axis to promote proliferation and metastasis in osteosarcoma.

Authors:  Xinyu Tan; Canjun Zeng; Haomiao Li; Yeru Tan; Hongbo Zhu
Journal:  Front Oncol       Date:  2022-08-18       Impact factor: 5.738

6.  PKIB involved in the metastasis and survival of osteosarcoma.

Authors:  Rongxue Wan; Gu Yang; Qianzhen Liu; Xiaokang Fu; Zengping Liu; Huilai Miao; Huan Liu; Wenhua Huang
Journal:  Front Oncol       Date:  2022-08-22       Impact factor: 5.738

Review 7.  Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors.

Authors:  Katia Scotlandi; Claudia Maria Hattinger; Evelin Pellegrini; Marco Gambarotti; Massimo Serra
Journal:  Cells       Date:  2020-04-14       Impact factor: 6.600

Review 8.  Bone Microenvironment and Osteosarcoma Metastasis.

Authors:  Chaofei Yang; Ye Tian; Fan Zhao; Zhihao Chen; Peihong Su; Yu Li; Airong Qian
Journal:  Int J Mol Sci       Date:  2020-09-23       Impact factor: 5.923

Review 9.  Osteosarcoma and Metastasis.

Authors:  Gaohong Sheng; Yuan Gao; Yong Yang; Hua Wu
Journal:  Front Oncol       Date:  2021-12-10       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.